References
- Hsia J, Otvos JD, Rossouw JE, et al. Lipoprotein particle concentrations may explain the absence of coronary protection in the Women’s Health Initiative hormone trials. Arterioscler Thromb Vasc Biol. 2008;28: 1666–1671.
- Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology foundation. Diabetes Care. 2008;31:811–822.
- Rosenson R, Davidson M, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010;213:1–7.
- Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the American Association for Clinical Chemistry Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55:407–419.
- Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on low-density and high-density lipoprotein particle concentrations in patients with the metabolic syndrome: A randomized, double-blind, controlled study. Diabetes Care. 2009;32:1087–1091.
- Jafri H, Alsheikh-Ali AA, Mooney P, Kimmelstiel CD, Karas RH, Kuvin JT. Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD. J Clin Lipidol. 2009;3:45–50.
- Cromwell WC, Otvos JD, Keyes M, et al. LDL Particle number and risk of future cardiovascular disease in the Framingham Offspring Study – implications for LDL management. J Clin Lipidol. 2007;1:583–592.
- Cromwell WC, Otvos JD. LDL particle number is highly heterogeneous among patients with type 2 diabetes at an LDL cholesterol target goal <100 mg/dL. Am J Cardiol 2006;98:1599–1602.
- Otvos J, Collins D, Freedman D, et al. VA-HIT: Low density lipoprotein and high density lipoprotein particle subclasses predict coronary events. Circulation. 2006;113:1556–1563.
- Jeyarajah E, Cromwell W, Otvos J. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26: 847–870.
- Cromwell WC, Bays HE, Toth PP. Lipoprotein subfraction analysis using nuclear magnetic resonance spectroscopy. In: Adams J, Apple F, Jaffe A, editors. Clinical Applications of Markers in Cardiology: A Case-Oriented Approach. London, UK: Blackstone; 2007.
- Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5:105–113.
- El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49:547–553.
- Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931–939.